Post navigation <\/p>\n
Authors:N. Momin, Eric;Mohyeldin, Ahmed;A. Zaidi, Hasan;Vela, Guillermo;Quinones-Hinojosa, Alfredo <\/p>\n
Abstract: <\/p>\n
Cellular therapies represent a new frontier in the treatment of neurological disease. Mesenchymal stem cells (MSCs), which can be harvested from bone marrow, adipose tissue, and umbilical cord blood, among many other sources, possess several qualities which may be used to treat diseases of the central nervous system. MSCs migrate to sites of malignancy, a property which may be used for the treatment of brain cancer. MSCs possess immunosuppressive properties, which may be used for the treatment of neurological disorders with an inflammatory etiology. Finally, MSCs restore injured neural tissue, a property which may be used for the treatment of neural injury. Approximately 23 clinical trials have been completed to date, with many more ongoing, and all have been listed in this review. The long-term safety of MSC-based therapies is not well established, and continues to be one major limitation to clinical translation. More broadly, only a small minority of clinical trials have employed rigorous designs that include prospective randomization, patients from multiple centers, clinically-relevant and reproducible endpoints, and adequate long-term follow-up. These limitations must be addressed before MSCs can enter widespread clinical use. Nevertheless, MSCs represent a promising new approach to treating diseases of the central nervous system that are traditionally associated with morbid outcomes. With additional pre-clinical and clinical studies that focus on their potential benefits as well as dangers, MSCs may one day find translation to clinical use in the setting of neurological disease. <\/p>\n<\/p>\n
Second University of Naples, Section of Pharmacology L. Donatelli, Department of Experimental Medicine, via S. Maria di Costantinopoli <\/p>\n
Recent studies have revealed that adult stem cells such as bone marrow-derived cells contribute to lung tissue regeneration and protection, and thus administration of exogenous stem\/progenitor cells may be a potent next-generation therapy for COPD. Pathogenesis of COPD is characterized by an upregulation of inflammatory processes leading to irreversible events such as apoptosis of epithelial cells, proteolysis of the terminal air-space and lung extracellular matrix components. The available pharmacological treatments are essentially symptomatic, therefore, there is a need to develop more effective therapeutic strategies. It has been previously demonstrated that transplanted MSC home to the lung in response to lung injury and adopt phenotypes of alveolar epithelial cells, endothelial cells, fibroblasts and bronchial epithelial cells. However, engraftment and differentiation are now felt to be rare occurrences and other mechanisms might be involved and play a more important role. Importantly, MSCs protect lung tissue through suppression of proinflammatory cytokines, and through triggering production of reparative growth factors. Accordingly, it is not clear if and how these cells will be able to repair, to slow or to prevent the disease. This article reviews recent advances in regenerative medicine in COPD and highlights that their potential application although promising and very attractive, are still a far away opinion. <\/p>\n<\/p>\n
Lasers, stem cells, and COPD <\/p>\n
Feng Lin1, Steven F Josephs1, Doru T Alexandrescu2, Famela Ramos1, Vladimir Bogin3, Vincent Gammill4, <\/p>\n
<\/p>\n
Read more: <\/p>\n
Uncategorized | Sarasota Stem Cell Therapy<\/a><\/p>\n","protected":false},"excerpt":{"rendered":" Post navigation Authors:N. Momin, Eric;Mohyeldin, Ahmed;A. Zaidi, Hasan;Vela, Guillermo;Quinones-Hinojosa, Alfredo Abstract: Cellular therapies represent a new frontier in the treatment of neurological disease Continue reading